Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China: A Nation-wide, Multi-center, Prospective, Non-interventional Study

NCT06846996 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06846996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06846996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China: A Nation-wide, Multi-center, Prospective, Non-interventional Study
Lead sponsor
Daiichi Sankyo
Phase
Observational
Overall status
Recruiting
Start date
February 27, 2025
Completion date
July 31, 2027
Enrollment
260 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive gastric cancer, her2-positive gastroesophageal junction